BRL 16.8
(-5.46%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 12.99 Billion BRL | -0.83% |
2022 | 13.1 Billion BRL | 31.21% |
2021 | 9.98 Billion BRL | 24.66% |
2020 | 8 Billion BRL | 149.55% |
2019 | 3.2 Billion BRL | 40.19% |
2018 | 2.28 Billion BRL | -4.32% |
2017 | 2.39 Billion BRL | -10.57% |
2016 | 2.67 Billion BRL | -65.67% |
2015 | 7.79 Billion BRL | 21.54% |
2014 | 6.41 Billion BRL | 18.22% |
2013 | 5.42 Billion BRL | -6.3% |
2012 | 5.78 Billion BRL | -13.34% |
2011 | 6.67 Billion BRL | 35.54% |
2010 | 4.92 Billion BRL | 72.9% |
2009 | 2.85 Billion BRL | 72.86% |
2008 | 1.64 Billion BRL | 29.03% |
2007 | 1.27 Billion BRL | 353.43% |
2006 | 281.82 Million BRL | 29.69% |
2005 | 217.3 Million BRL | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 13.34 Billion BRL | -1.52% |
2024 Q1 | 13.55 Billion BRL | 4.31% |
2023 Q3 | 12.87 Billion BRL | 0.94% |
2023 FY | 12.99 Billion BRL | -0.83% |
2023 Q2 | 12.75 Billion BRL | 8.97% |
2023 Q1 | 11.7 Billion BRL | -10.68% |
2023 Q4 | 12.99 Billion BRL | 0.94% |
2022 FY | 13.1 Billion BRL | 31.21% |
2022 Q1 | 10.47 Billion BRL | 4.9% |
2022 Q3 | 12.04 Billion BRL | 12.58% |
2022 Q2 | 10.7 Billion BRL | 2.18% |
2022 Q4 | 13.1 Billion BRL | 8.73% |
2021 Q2 | 8.96 Billion BRL | 4.02% |
2021 Q3 | 10.36 Billion BRL | 15.67% |
2021 Q4 | 9.98 Billion BRL | -3.69% |
2021 FY | 9.98 Billion BRL | 24.66% |
2021 Q1 | 8.61 Billion BRL | 7.58% |
2020 FY | 8 Billion BRL | 149.55% |
2020 Q4 | 8 Billion BRL | 3.0% |
2020 Q1 | 3.31 Billion BRL | 3.28% |
2020 Q2 | 6.58 Billion BRL | 98.61% |
2020 Q3 | 7.77 Billion BRL | 18.11% |
2019 Q2 | 1.96 Billion BRL | 3.48% |
2019 Q1 | 1.9 Billion BRL | -16.92% |
2019 FY | 3.2 Billion BRL | 40.19% |
2019 Q4 | 3.2 Billion BRL | 45.87% |
2019 Q3 | 2.2 Billion BRL | 11.8% |
2018 FY | 2.28 Billion BRL | -4.32% |
2018 Q4 | 2.28 Billion BRL | 10.27% |
2018 Q3 | 2.07 Billion BRL | 14.02% |
2018 Q2 | 1.82 Billion BRL | 2.85% |
2018 Q1 | 1.77 Billion BRL | -26.01% |
2017 Q4 | 2.39 Billion BRL | 26.37% |
2017 Q3 | 1.89 Billion BRL | -28.06% |
2017 Q2 | 2.63 Billion BRL | 24.31% |
2017 Q1 | 2.11 Billion BRL | -20.87% |
2017 FY | 2.39 Billion BRL | -10.57% |
2016 Q3 | 3.42 Billion BRL | -13.56% |
2016 FY | 2.67 Billion BRL | -65.67% |
2016 Q4 | 2.67 Billion BRL | -21.79% |
2016 Q2 | 3.95 Billion BRL | -7.45% |
2016 Q1 | 4.27 Billion BRL | -45.13% |
2015 Q2 | 6.58 Billion BRL | -1.91% |
2015 FY | 7.79 Billion BRL | 21.54% |
2015 Q4 | 7.79 Billion BRL | 9.44% |
2015 Q3 | 7.12 Billion BRL | 8.21% |
2015 Q1 | 6.7 Billion BRL | 4.64% |
2014 Q4 | 6.41 Billion BRL | 3.67% |
2014 Q3 | 6.18 Billion BRL | 6.14% |
2014 Q2 | 5.82 Billion BRL | 2.55% |
2014 FY | 6.41 Billion BRL | 18.22% |
2014 Q1 | 5.68 Billion BRL | 4.77% |
2013 Q1 | 5.68 Billion BRL | -1.83% |
2013 Q2 | 5.88 Billion BRL | 3.53% |
2013 Q3 | 6.28 Billion BRL | 6.78% |
2013 Q4 | 5.42 Billion BRL | -13.66% |
2013 FY | 5.42 Billion BRL | -6.3% |
2012 Q4 | 5.78 Billion BRL | -6.22% |
2012 Q1 | 6.35 Billion BRL | -4.85% |
2012 Q2 | 6.54 Billion BRL | 3.02% |
2012 Q3 | 6.17 Billion BRL | -5.74% |
2012 FY | 5.78 Billion BRL | -13.34% |
2011 Q1 | 6.29 Billion BRL | 27.75% |
2011 Q3 | 6.99 Billion BRL | 0.69% |
2011 Q2 | 6.94 Billion BRL | 10.32% |
2011 Q4 | 6.67 Billion BRL | -4.49% |
2011 FY | 6.67 Billion BRL | 35.54% |
2010 Q3 | 4.24 Billion BRL | 35.2% |
2010 FY | 4.92 Billion BRL | 72.9% |
2010 Q2 | 3.14 Billion BRL | 7.98% |
2010 Q4 | 4.92 Billion BRL | 16.02% |
2010 Q1 | 2.9 Billion BRL | 2.08% |
2009 Q4 | 2.85 Billion BRL | 0.0% |
2009 FY | 2.85 Billion BRL | 72.86% |
2008 FY | 1.64 Billion BRL | 29.03% |
2007 FY | 1.27 Billion BRL | 353.43% |
2006 FY | 281.82 Million BRL | 29.69% |
2005 FY | 217.3 Million BRL | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Blau FarmacĂȘutica S.A. | 1.05 Billion BRL | -1127.548% |